Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oren Rom

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Cell Metabolism|April 11, 2023
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primatesPengxiang Qu, Oren Rom, Ke Li, et al.
Blood Advances|January 9, 2026
Neutrophil CD14 is a Driver and a Therapeutic Target for Deep Vein ThrombosisNilesh Pandey, Harpreet Kaur, Raktim Mitra, et al.
Experimental Neurology|February 6, 2025
Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney diseaseHarpreet Kaur, Nilesh Pandey, Lakshmi Chandaluri, et al.
The Journal of Clinical Investigation|May 12, 2026
Metabolic dysfunction-associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109Pengxiang Qu, Shusi Ding, Yanru Zhang, et al.
Science Translational Medicine|December 3, 2020
Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiomeOren Rom, Yuhao Liu, Zhipeng Liu, et al.
Journal of Medicinal Chemistry|January 2, 2026
Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1Fabio Arias, Sumati Rohilla, Yudibeth Sixto-López, et al.
JHEP Reports : Innovation in Hepatology|March 4, 2026
Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosisSandeep Das, Sumit Kumar Anand, M Peyton McKinney, et al.
Nature Metabolism|September 27, 2024
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitisSandeep Das, Alexandra C Finney, Sumit Kumar Anand, et al.
Nature Communications|December 19, 2020
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular diseaseJonas B Nielsen, Oren Rom, Ida Surakka, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Cell Metabolism|April 11, 2023
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primatesPengxiang Qu, Oren Rom, Ke Li, et al.
Blood Advances|January 9, 2026
Neutrophil CD14 is a Driver and a Therapeutic Target for Deep Vein ThrombosisNilesh Pandey, Harpreet Kaur, Raktim Mitra, et al.
Experimental Neurology|February 6, 2025
Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney diseaseHarpreet Kaur, Nilesh Pandey, Lakshmi Chandaluri, et al.
The Journal of Clinical Investigation|May 12, 2026
Metabolic dysfunction-associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109Pengxiang Qu, Shusi Ding, Yanru Zhang, et al.
Science Translational Medicine|December 3, 2020
Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiomeOren Rom, Yuhao Liu, Zhipeng Liu, et al.
Journal of Medicinal Chemistry|January 2, 2026
Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1Fabio Arias, Sumati Rohilla, Yudibeth Sixto-López, et al.
JHEP Reports : Innovation in Hepatology|March 4, 2026
Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosisSandeep Das, Sumit Kumar Anand, M Peyton McKinney, et al.
Nature Metabolism|September 27, 2024
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitisSandeep Das, Alexandra C Finney, Sumit Kumar Anand, et al.
Nature Communications|December 19, 2020
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular diseaseJonas B Nielsen, Oren Rom, Ida Surakka, et al.
Pageof 8